The worth of controlling plasma lipids

American Journal of Cardiology

Volumn 81, Issue 8, 1998, Pages 1047-1049

  Kannel, William B ^a,b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Framingham Study   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATHEROGENESIS; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; DYSLIPIDEMIA; EDITORIAL; HUMAN; LIPID BLOOD LEVEL; MAINTENANCE THERAPY; MORTALITY; PRIORITY JOURNAL; THROMBOGENESIS; TREATMENT PLANNING;

ANTILIPEMIC AGENTS; CORONARY ARTERIOSCLEROSIS; COST-BENEFIT ANALYSIS; DIET; HUMANS; HYPERLIPIDEMIAS; LIPIDS; SURVIVAL RATE; UNITED STATES;

EID: 0032522780     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(98)00085-X     Document Type: Editorial

References (26)

1. Krut LH. On the statins, correct plasma lipid levels and preventing the clinical sequelae of atherosclerotic coronary heart disease: a critique. Am J Cardiol 1998;81:1045-1046.
2. Rossouw JE. Lipid-lowering interventions in angiographic trials. Am J Cardiol 1995;76:86C-92C.
3. Fuster V, Badimon L, Badimon L, Cheseboro J. The pathogenesis of coronary artery disease and the acute coronary syndromes. I. N Engl J Med 1992;326:242-250.
4. Fuster V, Badimon L, Badimon J. The pathogenesis of coronary artery disease and the acute coronary syndromes. II. N Engl J Med 1992;326:310-318.
5. Shepherd J, Cobb SM, Ford I, Isles CG, Lorimer AR, McFarlane PW, Mckillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-1307.
6. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease. The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
7. Austen MA, Breslow JL, Hennekens CH, Buring JE, Willett JE, Kraus RM. Low density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 1990;260:1917-1921.
8. Steinberg D, Witzum JL. Lipoproteins and atherogenesis: current concepts. JAMA 1990;264:3047-3051.
9. Kannel WB, Castelli WP, Gordon T. Lipoprotein cholesterol in the prediction of atherosclerotic disease: new perspectives based on the Framingham Study. Ann Intern Med 1979;90:85-91.
10. LaRosa JC, Hunninghake D, Bush D, Criqui MH, Getz GS, Gotto AM Jr, Grundy SM, Rakita L, Robertson RM, Weisfeldt ML. The cholesterol facts: a summary of the evidence relating dietary fats, serum cholesterol and coronary heart disease - a joint statement of the American Heart Association and the National Heart Lung and Blood Institute. Circulation 1990;81:1721-1733.
11. Kannel WB. Range of serum cholesterol values in the population developing coronary artery disease. Am J Cardiol 1995;76:69C-77C.
12. Johnson CL, Rifkind BM, Sempos CT, Carroll MD, Bachorik PS, Briefel RR, Gordon DJ, Burt VL, Brown CD, Lippel K. Declining serum cholesterol levels among US adults: The National Health and Nutrition Examination Surveys. JAMA 1993;269:3002-3008.
13. Kagan A, Harris BR, Winkelstein W Jr, Johnson KG, Kato H, Syme SL, Rhoads GG, Gay ML, Nichaman MZ, Hamilton HB, Tillotson J. Epidemiologic studies of coronary heart disease and stroke in Japanese men living in Japan, Hawaii, and California: demographic, physical, dietary and biochemical characteristics. J Chron Dis 1974;27:345-364.
14. Sytkowski PA, Kannel WB, D'Agostino RB. Changes in risk factors and the decline in mortality from cardiovascular disease. N Engl J Med 1990;322:1635-1646.
15. Spagnoli LG, Mauriello A, Orlandi A, Sangiorgi G, Bonanno E. Age-related changes affecting atherosclerotic risk. Potential for pharmacological intervention. Drugs Aging 1996;8:275-298.
16. Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD. Cholesterol reduction yields clinical benefit. A new look at old data. Circulation 1995;91:2274-2282.
17. Muldoon MF, Manuck SB, Matthews KA. Lowering cholesterol concentration and mortality; a quantitative review of primary prevention trials. Br Med J 1990;301:309-314.
18. Davey-Smith G, Song F, Sheldon TA. Cholesterol lowering and mortality: importance of considering initial level of risk. Br Med J 1993;306:1367-1368.
19. Law MR, Thompson SG. Assessing possible hazards of reducing serum cholesterol. Br Med J 1994;308:373-379.
20. Carlson LA, Rosenhamer G. Reduction in mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 1988;223:405-418.
21. Keech AC. Does cholesterol lowering reduce total mortality? Postgrad Med J 1992;68:870-871.
22. MacMahon S. Lowering cholesterol: effects on trauma death, cancer death and mortality. Aust NZ J Med 1992;22:580-582.
23. Law MR, Wald MJ. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? Br Med J 1994;308:367-372.
24. Holme I. Effects of lipid-lowering therapy on total and coronary mortality. Curr Opin Lipidol 1995;6:374-378.
25. Holme I. Relation between total mortality and cholesterol reduction as found by meta-regression analysis of randomized cholesterol-lowering trials. Control Clin Trials 1996;17:13-22.
26. Anderson KM, Wilson PWF, Odell PM, Kannel WB. An updated coronary risk profile: a statement for health professionals. Circulation 1991;83:356-362.